Bristol’s Dolan Advocates Fixed-Term Exclusivity As Plavix Faces Challenge

Bristol-Myers Squibb is approaching future patent applications with an eye toward early intellectual property challenges, CEO Peter Dolan stated during a Jan. 25 year-end earnings presentation